Yung‐Chi Cheng

13.0k total citations · 1 hit paper
272 papers, 10.4k citations indexed

About

Yung‐Chi Cheng is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Yung‐Chi Cheng has authored 272 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Molecular Biology, 113 papers in Infectious Diseases and 59 papers in Epidemiology. Recurrent topics in Yung‐Chi Cheng's work include HIV/AIDS drug development and treatment (106 papers), Biochemical and Molecular Research (58 papers) and HIV Research and Treatment (44 papers). Yung‐Chi Cheng is often cited by papers focused on HIV/AIDS drug development and treatment (106 papers), Biochemical and Molecular Research (58 papers) and HIV Research and Treatment (44 papers). Yung‐Chi Cheng collaborates with scholars based in United States, China and Taiwan. Yung‐Chi Cheng's co-authors include Lih‐Syng Lee, Wing Lam, Ginger E. Dutschman, Shwu-Huey Liu, Àngel Pellicer, Richard Axel, Saul J. Silverstein, Michael Wigler, Elizabeth A. Gullen and Zaoli Jiang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Yung‐Chi Cheng

269 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells

1977 1.2k citations Yung‐Chi Cheng et al. profile →

Peers

Countries citing papers authored by Yung‐Chi Cheng

Since Specialization

Citations

This map shows the geographic impact of Yung‐Chi Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yung‐Chi Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yung‐Chi Cheng more than expected).

Fields of papers citing papers by Yung‐Chi Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yung‐Chi Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yung‐Chi Cheng. The network helps show where Yung‐Chi Cheng may publish in the future.

Co-authorship network of co-authors of Yung‐Chi Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Yung‐Chi Cheng. A scholar is included among the top collaborators of Yung‐Chi Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yung‐Chi Cheng. Yung‐Chi Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting HINT1 to improve synaptic plasticity: toward loganin as a new antidepressant strategy 2025 ·Molecular Psychiatry ·Cong‐Yuan Xia, (unknown), Manni Wang, (unknown), Yuxuan Guo, Yan Han, (unknown), Yung‐Chi Cheng, Jie‐Kun Xu, Jun He, (unknown)	0
2	YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity 2023 ·Frontiers in Pharmacology ·Wing Lam, Rong Hu, Shwu-Huey Liu, (unknown), Yung‐Chi Cheng	6
3	YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy 2023 ·Frontiers in Pharmacology ·Wing Lam, (unknown), Wei Cai, Fulan Guan, Zaoli Jiang, Shwu-Huey Liu, (unknown), Yung‐Chi Cheng	1
4	Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β 2023 ·Acta Pharmacologica Sinica ·(unknown), (unknown), Jun Xu, (unknown), Yaming Shan, Yung‐Chi Cheng, (unknown), (unknown), Yuqiang Wang, Ying Wang	17
5	2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication 2020 ·Molecules ·Angela Corona, Valentina Onnis, Claudia Del Vecchio, Francesca Esposito, Yung‐Chi Cheng, Enzo Tramontano	11
6	Fischernolides A–D, four novel diterpene-based meroterpenoid scaffolds with antitumor activities fromEuphorbia fischeriana 2019 ·Organic Chemistry Frontiers ·Jia Zhang, Jun He, Yung‐Chi Cheng, Pei‐Cheng Zhang, Yu Yan, Haojun Zhang, Wei‐Ku Zhang, Jie‐Kun Xu	18
7	Fischeriana A, a meroterpenoid with an unusual 6/6/5/5/5/6/6 heptacyclic carbon skeleton from the roots of Euphorbia fischeriana 2019 ·Organic & Biomolecular Chemistry ·Jun He, Jie‐Kun Xu, Jia Zhang, Hongjin Bai, (unknown), Yung‐Chi Cheng, Wei‐Ku Zhang	20
8	Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant 2019 ·Cell chemical biology ·(unknown), R Harrison, Lun K. Tsou, (unknown), Brock A. Humphries, Deepa Rajasekaran, Gary D. Luker, (unknown), Jen‐Shin Song, (unknown), James W. Murphy, Yung‐Chi Cheng, Kak‐Shan Shia, Dimitrios Morikis, Elias Lolis	19
9	Natural deep eutectic characteristics of honey improve the bioactivity and safety of traditional medicines 2019 ·Journal of Ethnopharmacology ·Yuntao Dai, (unknown), Robert Verpoorte, Wing Lam, Yung‐Chi Cheng, (unknown), Jiang Xu, Liwei Zhang, Xuemei Qin, Shilin Chen	49
10	First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Muhammad Wasif Saif, Jia Li, Lynne Lamb, Kristin Kaley, (unknown), Zaoli Jiang, Scott Bussom, Shwu-Huey Liu, Yung‐Chi Cheng	61
11	DCB-3503, a Tylophorine Analog, Inhibits Protein Synthesis through a Novel Mechanism 2010 ·PLoS ONE ·Ying Wang, Wenli Gao, Yuri V. Svitkin, (unknown), Yung‐Chi Cheng	22
12	Abstract #4584: Exploration of the mechanisms of PHY906 in reducing the intestinal toxicity caused by irinotecan 2009 ·Cancer Research ·(unknown), Scott Bussom, Fulan Guan, Zaoli Jiang, Shwu-Huey Liu, Yung‐Chi Cheng	2
13	Mechanism of Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by a Stavudine Analogue, 4′-Ethynyl Stavudine Triphosphate 2008 ·Antimicrobial Agents and Chemotherapy ·Guangwei Yang, Jimin Wang, Yao Cheng, Ginger E. Dutschman, Hiromichi Tanaka, Masanori Baba, Yung‐Chi Cheng	14
14	ATP Modulates Poly(ADP-Ribose) Polymerase-1-Facilitated Topoisomerase I-Linked DNA Religation in the Presence of Camptothecin 2008 ·Molecular Pharmacology ·Shin‐Young Park, Chung‐Hang Leung, Yung‐Chi Cheng	8
15	PHY906 as a broad-spectrum enhancer in cancer therapy: Clinical and preclinical results in hepatocellular carcinoma 2006 ·Cancer Research ·Shwu-Huey Liu, (unknown), Zaoli Jiang, Rajendra Marathe, (unknown), (unknown), Robert D. Tilton, Yun Yen, Michal G. Rose, Samuel So, Edward Chu, Yung‐Chi Cheng	15
16	Synthesis and Biological Evaluation of 2′,3′-Didehydro-2′,3′-Dideoxy-9-Deazaguanosine, a Monophosphate Prodrug and Two Analogues, 2′,3′-Dideoxy-9-Deazaguanosine and 2′,3′-Didehydro-2′,3′-Dideoxy-9-Deazainosine 2005 ·Nucleosides Nucleotides & Nucleic Acids ·Mao‐Chin Liu, Mei‐Zhen Luo, (unknown), Ginger E. Dutschman, Elizabeth A. Gullen, Yung‐Chi Cheng, Alan C. Sartorelli	3
17	Characterization of sublines of Epstein-Barr virus producing HR-1 cells and its implication in virus propagation in culture 1995 ·Virus Genes ·Gang‐Qing Yao, Ching-Hwa Tsai, Yung‐Chi Cheng	5
18	High titers of anti‐epstein‐barr virus DNA polymerase are found in patients with severe fatiguing illness 1994 ·Journal of Medical Virology ·Benjamin H. Natelson, Ning Ye, Douglas E. Moul, Frank J. Jenkins, Dan A. Oren, Walter N. Tapp, Yung‐Chi Cheng	30
19	In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. 1992 ·Molecular Pharmacology ·John W. Mellors, Ginger E. Dutschman, Guang‐Jin Im, Enzo Tramontano, Susan Winkler, Yung‐Chi Cheng	120
20	Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4). 1985 ·PubMed ·Alan J. Townsend, Jean-Marie Leclerc, Ginger E. Dutschman, David A. Cooney, Yung‐Chi Cheng	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact